secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-064435
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics Q1 2025 net loss $136M; CTX310 Phase 1 shows up to 82% TG reduction
--------------------------------------------------------------------------------

- Net loss of $136.0M in Q1 2025, compared to $116.6M in Q1 2024; cash & equivalents $1.86B.
- CTX310 Phase 1 data: dose-dependent reductions in LDL (up to 81%) and TG (up to 82%) with well-tolerated safety.
- CASGEVY: >65 authorized treatment centers activated; ~90 patients with first cell collection; new initiations to grow in 2025.
- R&D expenses $72.5M, G&A $19.3M; collaboration expense net $57.5M (driven by CASGEVY and in vivo HSC editing).
- CTX320 (Lp(a)) dose escalation ongoing with update expected Q2 2025; CTX112/CTX131 CAR T updates mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017025064435/0000950170-25-064435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017025064435/crsp-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-064435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer